Business Context and Reporting Period
This Form 8-K, dated May 10, 2024, reports that Reneo Pharmaceuticals, Inc. (RPHM) has entered into a definitive Merger Agreement with OnKure, Inc. (OnKure). The transaction involves a reverse merger where OnKure will become the surviving entity, and Reneo will change its name to OnKure Therapeutics, Inc. The filing also details a concurrent private placement (PIPE) and changes to Reneo's executive leadership and equity plans.
Key Financial Metrics and Transaction Terms
- Valuation: The transaction values Reneo at $75.0 million and OnKure at $170.0 million.
- Ownership Structure: On a pro forma basis, pre-merger OnKure stockholders are expected to own approximately 69.4% of the combined company, while pre-merger Reneo stockholders will own approximately 30.6%.
- Concurrent PIPE Investment: Reneo has secured a commitment of $65.0 million from PIPE Investors to purchase shares of Reneo Class A Common Stock.
- Cash Conditions: The exchange ratio is subject to adjustment based on Reneo's net cash at closing. The ratio assumes a net cash position between $59.0 million and $61.0 million. Closing requires Reneo to have net cash of no less than $55.0 million.
- Termination Fees: A termination fee of $3.0 million is payable by Reneo to OnKure under specified circumstances, and vice versa.
Material Changes and Corporate Actions
- Merger Structure: The transaction is structured as a tax-free reorganization involving two merger steps to integrate OnKure into Reneo's corporate structure.
- Stockholder Proposals: Reneo stockholders must approve a reverse stock split, the issuance of shares for the merger and PIPE, the name change to OnKure Therapeutics, Inc., and the creation of non-voting Class B common stock.
- Executive Changes: Reneo's current executive officers (Gregory J. Flesher, Alejandro Dorenbaum, Jennifer Lam, and Ashley F. Hall) are expected to resign upon closing. OnKure's Nicholas A. Saccomano and Jason Leverone are expected to become the new President/CEO and CFO, respectively.
- Equity Adjustments: Reneo approved the acceleration of vesting for certain equity awards held by departing executives and modified exercise windows for stock options.
Outlook, Risks, and Contingencies
- Closing Conditions: The merger is contingent on stockholder approval from both companies, effectiveness of the Form S-4 registration statement, Nasdaq listing approval, and the receipt of PIPE funds.
- Lock-Up Agreements: OnKure executives, directors, and certain stockholders, along with remaining Reneo directors, have agreed to a 180-day lock-up period on their shares post-closing.
- Risks: The filing highlights risks regarding the failure to satisfy closing conditions, regulatory delays, the early-stage nature of OnKure's product candidates, and the potential for the combined company to incur significant net losses.
- Management Commentary: The transaction is intended to provide OnKure with a public listing and capital to advance its product candidates, while leveraging Reneo's existing public infrastructure.
Investor Verification Checklist
- Verify the final net cash position of Reneo prior to closing to confirm the exact exchange ratio and ownership percentages.
- Review the upcoming Form S-4 and Proxy Statement for detailed financial data and risk factors not fully disclosed in this 8-K.
- Confirm the status of the $65.0 million PIPE investment and the identity of the participating investors.
- Monitor the timeline for stockholder votes and the effectiveness of the registration statement.
- Assess the clinical development status and regulatory pathway of OnKure's product candidates as the primary value driver of the combined entity.